Exocyclic amine substituted coumarin compounds and their use as fluorescent labels.
Exocyclic amine-substituted coumarin derivatives address the challenges of multiplex fluorescence detection in nucleic acid sequencing by providing improved fluorescence properties and photostability, leading to enhanced detection and sequencing accuracy under blue light excitation.
Patent Information
- Application Number
- JP2020572446
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-03-01
- Filing Date
- 2020-02-28
- Publication Date
- 2024-11-20
- Estimated Expiration
- 2040-02-28
AI Technical Summary
Existing fluorescent dyes for nucleic acid sequencing face challenges such as difficulty in finding dyes with appropriately resolved absorption and emission spectra, simultaneous excitation leading to complex signals, and insufficient photostability under high-power light sources, limiting the efficiency and accuracy of multiplex fluorescence detection.
Development of exocyclic amine-substituted coumarin derivatives that absorb short wavelength light, particularly around 450-460 nm, allowing for improved fluorescence detection and resolution in nucleic acid sequencing, with enhanced photostability and compatibility with biological buffers and enzymes.
The new fluorescent compounds enable higher density detection and improved sequencing accuracy by reducing wavelength emission, enhancing the length, intensity, and quality of sequencing reads, particularly under blue light excitation.
Smart Images

Figure 0007587424000056 
Figure 0007587424000057 
Figure 0007587424000058
Abstract
Description
[Technical field]
[0001] (Incorporation by reference of priority application) This application claims the benefit of priority to U.S. Provisional Application No. 62 / 812,837, filed March 1, 2019, which is incorporated by reference in its entirety.
[0002] (Field) The present disclosure relates to exocyclic amine-substituted coumarin derivatives and their use as fluorescent markers. In particular, these compounds can be used as fluorescent labels for nucleotides in nucleic acid sequencing applications. [Background technology]
[0003] (background) Several publications and patent documents are referenced in this application in order to more fully describe the state of the art to which this disclosure pertains. The disclosures of each of these publications and documents are incorporated herein by reference.
[0004] Non-radioactive detection of fluorescently labeled nucleic acids is an important technique in molecular biology. Many procedures used in recombinant DNA technology were previously 32 Previous methods have relied on the use of nucleotides or polynucleotides radioactively labeled with P. Radioactive compounds allow for sensitive detection of nucleic acids and other molecules of interest. However, the use of radioisotopes has serious limitations, including cost, limited shelf life, poor sensitivity, and more importantly, safety considerations. Eliminating the need for radioactive labeling reduces both safety risks and environmental impacts and costs associated with disposal of reagents, etc. Suitable methods for non-radioactive fluorescence detection include, by way of non-limiting example, automated DNA sequencing, hybridization methods, real-time detection of polymerase chain reaction products, and immunoassays. Summary of the Invention [Problem to be solved by the invention]
[0005] For many applications, it is desirable to use multiple spectrally distinguishable fluorescent labels to achieve independent detection of multiple spatially overlapping analytes.Such multiplex methods can reduce the number of reaction vessels, simplify experimental protocols, and facilitate the production of application-specific reagent kits.In multi-color automated DNA sequencing systems, for example, multiplex fluorescent detection allows the analysis of multiple nucleotide bases in a single electrophoretic lane, increasing throughput compared to single-color methods and reducing the uncertainty associated with lane-to-lane electrophoretic mobility variations.
[0006] However, multiplexed fluorescence detection can be problematic, and there are a number of important factors that constrain the selection of suitable fluorescent labels. First, it can be difficult to find dye compounds with adequately resolved absorption and emission spectra for a given application. Also, when several fluorescent dyes are used together, simultaneous excitation can complicate the fluorescent signals produced in distinguishable spectral regions, since the dye absorption bands are usually widely separated, making it difficult to achieve reasonable fluorescence excitation efficiency even with two dyes. Many excitation methods use high-power light sources such as lasers, so the dyes must be photostable enough to withstand such excitation. A final consideration, particularly important for molecular biology methods, is how compatible the fluorescent dye must be with the reagent chemistry, e.g., DNA synthesis solvents and reagents, buffers, polymerase enzymes, and ligase enzymes.
[0007] As sequencing technology advances, there is a need for additional fluorescent dye compounds, their nucleic acid conjugates, and multiplexed dye sets that meet all the above constraints and are particularly suitable for high-throughput molecular methods such as solid-phase sequencing.
[0008] Fluorescent dye molecules with improved fluorescence properties, such as suitable fluorescence intensity, shape, and wavelength maximum of fluorescence, can improve the speed and accuracy of nucleic acid sequencing. A strong fluorescent signal is especially important when measurements are performed in water-based biological buffers and at high temperatures, since the fluorescence intensity of most dyes is significantly lower under such conditions. And the nature of the base to which the dye is attached also affects the fluorescence maximum, fluorescence intensity, and other spectral dye properties. Sequence-specific interactions between nucleic acid bases and fluorescent dyes can be tailored by specific design of the fluorescent dye. Optimization of the fluorescent dye structure can improve the efficiency of nucleotide incorporation, reduce the level of sequencing errors, and reduce the amount of reagents used in nucleic acid sequencing, thus reducing costs.
[0009] Several optical and technological developments have already led to greatly improved image quality, but ultimately were limited by poor optical resolution. In general, the optical resolution of optical microscopes is limited to objects spaced at approximately half the wavelength of the light used. Thus, in practice, optical microscopes can only resolve objects that are quite far apart (at least 200-350 nm). One way to improve image resolution and increase the number of resolvable objects per unit surface area is to use excitation light with a shorter wavelength. For example, shortening the wavelength of light by Δλ~100 nm for the same optical system results in better resolution (approximately Δ50 nm / (approximately 15%)), records images with less distortion, and increases the density of objects that can be recognized by approximately 35%.
[0010] Certain nucleic acid sequencing methods use laser light to excite and detect dye-labeled nucleotides. These instruments use longer wavelength light, such as a red laser, with the appropriate dyes excitable at 660 nm. To detect more densely packed nucleic acid sequencing clusters while maintaining useful resolution, a shorter wavelength blue light source (450-460 nm) may be used. In this case, the optical resolution would not be limited by the emission wavelength of the longer wavelength red fluorescent dyes, but rather by the emission of the dyes excitable by the next longest wavelength light source, e.g., a "green laser" at 532 nm. Thus, there is a need for blue dye labels for use in fluorescence detection for sequencing applications.
[0011] Although blue dye chemistry and associated laser technology have been refined to produce dyes for, for example, DVDs and Blu-ray® discs, these compounds are not suitable for biolabeling and cannot be used as biomarkers.
[0012] Unfortunately, commercially available blue dyes with strong fluorescence suitable for nucleotide labeling are still very rare. Described herein are novel fluorescent compounds suitable for nucleotide labeling with strong fluorescence under blue light excitation. [Means for solving the problem]
[0013] (overview) The present disclosure relates to exocyclic amine substituted coumarin derivatives. These compounds may be useful as fluorescent labels, particularly for nucleotide labeling in nucleic acid sequencing applications. In some embodiments, the dyes absorb short wavelength light, optimally at wavelengths between 450 and 460 nm, and are particularly advantageous in situations where blue wavelength excitation sources having wavelengths between 450 and 460 nm are used. Blue wavelength excitation allows for detection and resolution of higher density features per unit area due to shorter wavelengths of fluorescent emission. When such dyes are used in conjugates with nucleotides, improvements can be seen in the length, intensity, accuracy, and quality of sequencing reads obtained during nucleic acid sequencing methods.
[0014] Some embodiments of the present disclosure relate to a compound of formula (I) or a salt thereof: [ka] In the formula, X is O, S, Se, or NR n Where R n , H, C 1-6 Alkyl or C 6-10 is aryl; Ring A is a 3- to 10-membered heterocyclyl; R, R 1 , R 2 , and R 4 are each independently H, halo, -CN, -CO2H, amino, -OH, C-amido, N-amido, NO2, -SO3H, -SO2NR a R b , optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aminoalkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; Each R 3 are independently halo, -CN, -CO2H, -(CH2) p -CO2R c , -(CH2) q -C(O)NR d R e , Amino, -OH, C-Amido, N-Amido, -NO2, -SO3H, -SO2NR a R b , optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or two R 3 forms an oxo (=O); p and q are each 1, 2, 3, or 4; Each R 5are independently halo, -CN, -COR f , Amino, -OH, C-Amido, N-Amido, -NO2, -SO3H, -SO2NR a R b , optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aminoalkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; Each R a and R b are independently H or optionally substituted C 1-6 is alkyl; Each R c , R d , R e and R f are independently H, optionally substituted C 1-6 alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; m is 0, 1, 2, 3, or 4; and n is 0, 1, 2, 3, 4, or 5. In some embodiments, at least one of m or n is not 0. In some further embodiments, R, R 1 , R 2 , and R 4 When each of R, R is H, at least one of m or n is not 0. 1 , R 2 , and R 4 Each of R, R is H, and when m is 0, n is 1, 2, 3, 4, or 5. 1 , R 2 , and R 4 is H and when n is 0, m is 1, 2, 3, or 4. In some embodiments, m is 1; R 5 is -COH; R, R 1 , R 2 , R 4 each of is H; ring A is [ka] where X is O, Se, or NR n It is.
[0015] In some other embodiments, the compounds of the present disclosure are conjugated to a substrate moiety, such as, for example, a nucleoside, a nucleotide, a polynucleotide, a polypeptide, a carbohydrate, a ligand, a particle, a cell, a semi-solid surface (e.g., a gel), or a solid surface. Conjugation may be performed through a carboxyl group (-CO2H), which can react with an amino or hydroxyl group on a moiety (such as a nucleotide) or a linker attached thereto to form an amide or ester, using methods known in the art.
[0016] Some other aspects of the present disclosure relate to dye compounds that include a linker group that allows for, for example, covalent attachment to a substrate moiety. The attachment may be at any position on the dye, including any of the R groups. In some embodiments, the attachment is at the R 3 via or R 5 It may also be carried out via
[0017] Some further aspects of the present disclosure provide nucleoside or nucleotide compounds defined by the formula: NL-Dye where N is a nucleotide; L is an optional linker moiety; and Dye is a fluorescent compound according to the present disclosure.
[0018] Some additional embodiments described herein relate to moieties, particularly nucleotides or oligonucleotides, labeled with a compound of formula (I).
[0019] Some additional disclosures provide methods of sequencing using the dye compounds of the present disclosure.
[0020] According to a further aspect, the present disclosure also provides a kit that includes dye compounds (free or conjugated form) that can be used in various immunological assays, oligonucleotide or nucleic acid labeling, or for DNA sequencing by synthesis.In yet another aspect, the present disclosure provides a kit that includes a dye "set" that is particularly suitable for the cycle of sequencing by synthesis on an automated instrument platform.In some aspects, the kit includes one or more nucleotides, at least one of which is a labeled nucleotide as described herein.
[0021] A further aspect of the present disclosure are chemical formulations of the compounds of the present disclosure that include moieties such as exocyclic amine-substituted coumarin dyes and nucleotides labeled with such dyes.
[0022] In a further aspect is a method of sequencing comprising incorporating a labeled nucleotide as described herein into a polynucleotide in a sequencing assay and detecting the incorporated labeled nucleotide. [Brief description of the drawings]
[0023] [Figure 1] FIG. 1 is a scatter plot showing the utility of fully functionalized A nucleotides labeled with dye I-4 as described herein in a two-channel sequencing analysis. [Diagram 2] FIG. 2 is a scatter plot showing the utility of fully functionalized A nucleotides labeled with dye I-5 as described herein in a two-channel sequencing analysis. [Diagram 3] FIG. 3 is a scatter plot showing the utility of fully functionalized A nucleotides labeled with dye I-6 as described herein in a two-channel sequencing analysis. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0024] (Detailed Description) The present disclosure provides exocyclic amine substituted coumarin compounds that are particularly suitable for methods of fluorescence detection and sequencing by synthesis. The embodiments described herein relate to dyes of the structure of formula (I) and their derivatives, salts and mesomeric forms thereof: [ka]
[0025] In some embodiments, X is O. In some embodiments, X is S. In some embodiments, X is Se. In some embodiments, X is NR n and R n , H, C 1-6 Alkyl, or C 6-10 aryl, and in one aspect, R n is H. In some further embodiments, m is 1; R 5 is -COH; R, R 1 , R 2 , R 4 each of is H; ring A is [ka] where X is O, Se, or NR n In some further embodiments, n is 0; and ring A is [ka] and;R,R 1 , R 2 , R 4 is H; when X is O; and m is 1, 2, 3, or 4. In some embodiments, when n is 0, m is 1, 2, 3, or 4, and at least one R 5 In some other embodiments, n is 1 and R 3 is -COH, m is 0, or R 5 is not -CO2H.
[0026] In some embodiments, R is H, halo, -COH, amino, -OH, C-amido, N-amido, -NO, -SOH, -SONH, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aminoalkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In one embodiment, R is H. In another embodiment, R is halo. In some embodiments, R is optionally substituted C 1-6 In some embodiments, R is -COH. In some embodiments, R is -SOH. In some embodiments, R is -SONR. a R b Where R a and R b are independently H or optionally substituted C 1-6 In one embodiment, R is -SO2NH2. In some embodiments, R is not -CN.
[0027] In some embodiments, R 1 is H. In some embodiments, R 1 is halo. In some embodiments, R 1 In some embodiments, R 1 Ha, ha C 1-6 In some embodiments, R 1 is -SO2NR a R b Where R a and R b are independently H or optionally substituted C 1-6 In one embodiment, R 1 In some embodiments, R 1 is not -CN.
[0028] In some embodiments, R 2 is H. In some embodiments, R 2 is halo. In some embodiments, R 2is -SO3H. In some embodiments, R 2 is optionally substituted alkyl, e.g., C 1-6 In some further embodiments, R 2 is C optionally substituted with -CO2H or -SO3H 1-4 It is an alkyl.
[0029] In some embodiments, R 4 is H. In some embodiments, R 4 is -SO3H. In some embodiments, R 4 is optionally substituted alkyl, e.g., C 1-6 In some further embodiments, R 4 is C optionally substituted with -CO2H or -SO3H 1-4 It is an alkyl.
[0030] In some embodiments, ring A is a 3-7 membered single heterocyclic ring. In some further embodiments, the 3-7 membered single heterocyclic ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. In some further embodiments, the 3-7 membered single heterocyclic ring contains one nitrogen atom. In some embodiments, ring A is [ka] In one such embodiment, ring A is [ka] In some embodiments, ring A is [ka] In one such embodiment, ring A is [ka] In some embodiments, ring A is [ka] In one such embodiment, ring A is [ka] In some embodiments of Ring A described herein, n is 0. In some embodiments of Ring A described herein, n is 1. In some embodiments of Ring A described herein, n is 2 or 3. In some embodiments, each R 3 are independently -CO2H, -SO3H, C optionally substituted with -CO2H or -SO3H 1-4 Alkyl, -(CH2) p -CO2R c , or optionally substituted C 1-6 In some embodiments, R 3 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, or hexyl. 3 , is replaced by C 1-4 In some embodiments, R 3 is C substituted with -CO2H or -SO3H 1-4 Alkyl or C 2-6 In some further embodiments, n is 1 and R 3 is -CO2H or -(CH2) p -CO2R c In some further embodiments, R c is H or C 1-4 It is an alkyl.
[0031] Of formula (I) [ka] The benzene ring of the moiety is R 5 When m is zero, the benzene ring is unsubstituted. When m is greater than 1, each R 5may be the same or different. In some embodiments, m is 0. In other embodiments, m is 1. In other embodiments, m is 2. In some embodiments, m is 1, 2, or 3, and each R 5 are independently halo, -CN, -COR f , Amino, -OH, -SO3H, -SO2NR a R b , or optionally substituted C 1-6 Alkyl, R f is H or C 1-4 In some further embodiments, R 5 is -CO2H, -SO3H, -SO2NH2, or C substituted with -CO2H, -SO3H, or -SO2NH2 1-6 In some further embodiments, R 5 is -(CH2) x COOH, where x is 2, 3, 4, 5, or 6. In some embodiments, R, R 1 , R 2 , R 4 When each of the following is H; n is 0; and m is 1; [ka] is substituted in the following positions: [ka] In one embodiment, R 5 is -COH.
[0032] Particular examples of compounds of formula (I) include those where X is O, S or NH; Each R, R 1 , R 2 , and R 4 is H; ring A is [ka] n is 0 or 1; R 3 -CO2H or -(CH2) p -CO2Rc p is 1, 2, 3, or 4; R c But H or C 1-6 alkyl; m is 0 or 1; and R 5 But, halo, -CO2R f , -SO3H, -SO2NR a R b , or SO3H or -SO2NR a R b C replaced with 1-6 In some embodiments, R a and R b At least one or both of 1-6 In some further embodiments, R f is H or C 1-4 In some further embodiments, when m is 0, n is 1; or when n is 0, m is 1. In one embodiment, both m and n are 1. In some further embodiments, when m is 1, [ka] is substituted in the following positions: [ka] In one embodiment, R 5 is -COH. In another embodiment, R 5 is halo, such as chloro, or -SO3H. In yet another embodiment, R 5 is -SO2NR a R b Where R a and R b At least one or both of the following is H or C 1-6 It is an alkyl.
[0033] Particular examples of compounds of formula (I) include those in which X is O, S or NH; 1 , R 2 , and R 4 is H; ring A is [ka] n is 0 or 1; R 3 -CO2H or -(CH2) p -CO2R c p is 1, 2, 3, or 4; Rc is H or C 1-6 m is 0 or 1; R is halo, -COR f , -SO3H, SO2NR a R b or -SO3H or -SO2NR a R b C replaced with 1-6 In some embodiments, R a and R b At least one or both of 1-6 In some further embodiments, R f is H or C 1-4 In some further embodiments, when m is 0, n is 1; or when n is 0, m is 1. In one embodiment, both m and n are 1. In some further embodiments, when m is 1, [ka] is substituted in the following positions: [ka] In one embodiment, R 5 is -COH. In another embodiment, R 5 is halo, such as chloro, or -SO3H. In yet another embodiment, R 5 is -SO2NR a R b Where R a and R b At least one or both of the following is H or C 1-6 It is an alkyl.
[0034] Particular examples of compounds of formula (I) include those in which X is O, S or NH; 1 , R 2 , and R 4 is H; ring A is [ka] n is 0 or 1; R 3 -CO2H or -(CH2) p -CO2R c p is 1, 2, 3, or 4; R c But H or C 1-6 m is 0 or 1; R 5 But, halo, -CO2R f , -SO3H, -SO2NR a R b or -SO3H or -SO2NR a R b C replaced with 1-6 In some embodiments, R a and R b At least one or both of 1-6 In some further embodiments, R f is H or C 1-4 In some further embodiments, when m is 0, n is 1; or when n is 0, m is 1. In one embodiment, both m and n are 1. In some further embodiments, when m is 1, [ka] is substituted in the following positions: [ka] In one embodiment, R 5 is -COH. In another embodiment, R 5 is halo, such as chloro, or -SO3H. In yet another embodiment, R 5 is -SO2NR a Rb Where R a and R b At least one or both of the following is H or C 1-6 It is an alkyl.
[0035] Specific examples of exocyclic amine substituted coumarin dyes include the following: [ka] [ka] and their salts and mesomeric forms.
[0036] Particularly useful compounds are nucleotides or oligonucleotides labeled with the dyes described herein. The labeled nucleotides or oligonucleotides can be linked to the dye compounds disclosed herein via a carboxy or alkyl-carboxy group to form an amide or alkyl-amide. For example, the dye compounds disclosed herein can be represented by the formula (I): R 3 or R 5 In some embodiments, R of formula (I) is linked to the nucleotide or oligonucleotide via 3 is -CO2H or -(CH2) p In some embodiments, R of formula (I) is -COH, and the bond forms an amide using the -COH group. 5 is -CO2H and the bond forms an amide using the -CO2H group. The labeled nucleotide or oligonucleotide can have a label attached via a linker moiety to the C5 position of a pyrimidine base or the C7 position of a 7-deazapurine base.
[0037] The labeled nucleotide or oligonucleotide may also have a blocking group covalently attached to the ribose or deoxyribose sugar of the nucleotide. The blocking group may be attached to any position of the ribose or deoxyribose sugar. In a particular embodiment, the blocking group is at the 3'OH position of the ribose or deoxyribose sugar of the nucleotide.
[0038] Provided herein is a kit comprising two or more nucleotides, at least one of which is a nucleotide labeled with a compound of the present disclosure. The kit may comprise two or more labeled nucleotides. The nucleotide may be labeled with two or more fluorescent labels. The two or more labels may be excited using a single excitation source, which may be a laser. For example, the excitation bands of the two or more labels may at least partially overlap, such that excitation in the overlapping region of the spectrum causes both labels to fluoresce. In particular embodiments, the emission from the two or more labels will occur in different regions of the spectrum, such that the presence of at least one of the labels can be determined by optically distinguishing the emission.
[0039] The kit may include four labeled nucleotides, the first of which is labeled with a compound as disclosed herein. In such a kit, each of the four nucleotides may be labeled with the same or different compound as the label of the other three nucleotides. Thus, one or more compounds may have a distinct absorbance and / or emission maximum, such that the compound can be distinguished from the other compounds. For example, each compound may have a distinct absorbance and / or emission maximum, such that each compound can be distinguished from the other three compounds. It will be understood that portions of the absorbance and / or emission spectrum other than the maximum may differ, and these differences may be used to distinguish the compounds. The kit may be such that two or more compounds have a distinct absorbance maximum. The compounds of the present invention typically absorb light in the region below 500 nm.
[0040] The compounds, nucleotides, or kits described herein may be used to detect, measure, or identify biological systems, including, for example, processes or components thereof. Exemplary techniques that the compounds, nucleotides, or kits may be used for include sequencing, expression analysis, hybridization analysis, genetic analysis, RNA analysis, cell assays (e.g., cell binding or cell function analysis), or protein assays (e.g., protein binding assays or protein activity assays). They may be used in automated instruments to perform certain techniques, such as automated sequencing instruments. Sequencing instruments may include two lasers that operate at different wavelengths.
[0041] Disclosed herein is a method for synthesizing the compounds of the present disclosure. The dyes according to the present disclosure can be synthesized from a variety of different suitable starting materials. For example, the compound of formula (I) may be prepared by reacting the compound of formula (II) with an optionally substituted cyclic amine of formula (III): [ka] where the variables X, R, R 1 , R 2 , R 3 , R 4 , R 5 , ring A, m, and n are each defined herein. The reaction may be carried out in an organic solvent at ambient or elevated temperature.
[0042] (definition) The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.
[0043] It should be noted that, as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless expressly and unambiguously limited to one referent. It will be apparent to those skilled in the art that various modifications and variations can be made to the various embodiments described herein without departing from the spirit or scope of the present teachings. Accordingly, the various embodiments described herein are intended to cover other modifications and variations within the scope of the appended claims and their equivalents.
[0044] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art. Use of the term "including" and other forms such as "include", "includes", "included" is not limiting. Use of the term "having" and other forms such as "have", "has", "had" is not limiting. As used herein, whether in a transitional phrase or in the body of a claim, the terms "comprise(s)" and "comprising" should be construed to have an open-ended meaning. That is, the above terms should be construed synonymously with the phrases "having at least" or "including at least". For example, when used in the context of a process, the term "comprising" means that the process includes at least the recited steps, but may include additional steps. When used in the context of a compound, composition, or device, the term "comprising" means that the compound, composition, or device includes at least the recited features or components, but may also include additional features or components.
[0045] As used herein, the term "covalently attached" or "covalently bonded" refers to the formation of a chemical bond characterized by the sharing of electron pairs between atoms. For example, a covalently attached polymer coating refers to a polymer coating that forms a chemical bond with the functionalized surface of a substrate, as compared to bonding to the surface via other means, such as adhesion or electrostatic interactions. It will be understood that the polymer that is covalently attached to a surface can also be attached via means in addition to covalent bonds.
[0046] As used herein, the term "halogen" or "halo" means any one of the radiation-stable atoms in column 7 of the periodic table of the elements, e.g., fluorine, chlorine, bromine, or iodine, with fluorine and chlorine being preferred.
[0047] As used herein, "alkyl" refers to a straight or branched hydrocarbon chain that is fully saturated (i.e., contains no double or triple bonds). The alkyl group may have 1 to 20 carbon atoms (wherever it appears in this specification, a numerical range such as "1 to 20" refers to each integer within the specified range; for example, "1 to 20 carbon atoms" means that the alkyl group may consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to 20 carbon atoms, but this definition also covers occurrences of the term "alkyl" where no numerical range is specified). The alkyl group may also be a medium-sized alkyl having 1 to 9 carbon atoms. The alkyl group could also be a lower alkyl having 1 to 6 carbon atoms. The alkyl group may also be a "C 1-4 Alkyl" or similar designations. 1-6 "Alkyl" indicates that there are 1 to 6 carbon atoms in the alkyl chain, i.e., the alkyl chain is selected from the group consisting of methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, and t-butyl. Typical alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, pentyl, hexyl, and the like.
[0048] As used herein, "alkoxy" refers to the formula -OR, where R is alkyl as defined above, e.g., "C 1-9 Alkoxy" includes, but is not limited to, methoxy, ethoxy, n-propoxy, 1-methylethoxy (isopropoxy), n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy, and the like.
[0049] As used herein, "alkenyl" refers to a straight or branched hydrocarbon chain containing one or more double bonds. Alkenyl groups can have from 2 to 20 carbon atoms, although this definition also covers occurrences of the term "alkenyl" where no numerical range is specified. Alkenyl groups can also be medium-sized alkenyls having from 2 to 9 carbon atoms. Alkenyl groups can also be lower alkenyls having from 2 to 6 carbon atoms. Alkenyl groups may also be designated as "C2-6 alkenyl" or similar designations. By way of example only, "C2-6 alkenyl" indicates that there are 2 to 6 carbon atoms in the alkenyl chain, i.e., the alkenyl chain is selected from the group consisting of ethenyl, propen-1-yl, propen-2-yl, propen-3-yl, buten-1-yl, buten-2-yl, buten-3-yl, buten-4-yl, 1-methyl-propen-1-yl, 2-methyl-propen-1-yl, 1-ethyl-ethen-1-yl, 2-methyl-propen-3-yl, buta-1,3-dienyl, buta-1,2,-dienyl, and buta-1,2-dien-4-yl. Exemplary alkenyl groups include, but are not limited to, ethenyl, propenyl, butenyl, pentenyl, hexenyl, and the like.
[0050] As used herein, "alkynyl" refers to a straight or branched hydrocarbon chain containing one or more triple bonds. An alkynyl group can have from 2 to 20 carbon atoms, although this definition also covers occurrences of the term "alkynyl" where no numerical range is specified. An alkynyl group could also be a medium alkynyl having from 2 to 9 carbon atoms. An alkynyl group could also be a lower alkynyl having from 2 to 6 carbon atoms. An alkynyl group is defined as "a group having from 2 to 20 carbon atoms, but this definition also covers occurrences of the term "alkynyl" where no numerical range is specified. An alkynyl group could also be a medium alkynyl having from 2 to 9 carbon atoms. An alkynyl group could also be a lower alkynyl having from 2 to 6 carbon atoms. 2-6 alkynyl" or similar designations. 2-6 "Alkynyl" indicates that there are 2 to 6 carbon atoms in the alkynyl chain, i.e., the alkynyl chain is selected from the group consisting of ethynyl, propyn-1-yl, propyn-2-yl, butyn-1-yl, butyn-3-yl, butyn-4-yl, and 2-butynyl. Typical alkynyl groups include, but are not limited to, ethynyl, propynyl, butynyl, pentynyl, hexynyl, and the like.
[0051] As used herein, "heteroalkyl" refers to a straight or branched hydrocarbon chain containing one or more heteroatoms, i.e., elements other than carbon, including but not limited to nitrogen, oxygen, and sulfur, in the chain backbone. Heteroalkyl groups can have from 1 to 20 carbon atoms, although this definition also covers occurrences of the term "heteroalkyl" where no numerical range is specified. Heteroalkyl groups could also be medium-sized heteroalkyls having from 1 to 9 carbon atoms. Heteroalkyl groups could also be lower heteroalkyls having from 1 to 6 carbon atoms. Heteroalkyl groups are defined as "heteroalkyl groups" that are either "C 1-6 A heteroalkyl group may be designated as "heteroalkyl" or similar designations. A heteroalkyl group may contain one or more heteroatoms. By way of example only, "C 4-6 "Heteroalkyl" indicates that the heteroalkyl chain has from 4 to 6 carbon atoms and further includes one or more heteroatoms in the backbone of the chain.
[0052] The term "aromatic" refers to a ring or ring system having a conjugated pi-electron system, and includes both carbocyclic aromatic (e.g., phenyl) and heterocyclic aromatic (e.g., pyridine) groups. The term includes monocyclic or fused-ring polycyclic (i.e., rings which share adjacent pairs of atoms) groups, provided that the entire ring system is aromatic.
[0053] As used herein, "aryl" refers to an aromatic ring or ring system (i.e., two or more fused rings that share two adjacent carbon atoms) that contains only carbon in the ring backbone. When aryl is a ring system, all rings in the system are aromatic. Aryl groups can have from 6 to 18 carbon atoms, although this definition also covers occurrences of the term "aryl" where no numerical range is specified. In some embodiments, aryl groups have from 6 to 10 carbon atoms. An aryl group is defined as "C 6-10 Aryl, C6 or C 10 The group may be designated as "aryl" or similar designations. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, azulenyl, and anthracenyl.
[0054] "Aralkyl" or "arylalkyl" means "C 7-14 Aryl groups bonded as a substituent through an alkylene group, such as "aralkyl," include, but are not limited to, benzyl, 2-phenylethyl, 3-phenylpropyl, and naphthylalkyl. In some cases, the alkylene group may be joined to a lower alkylene group (i.e., C 1-6 alkylene group).
[0055] As used herein, "heteroaryl" refers to an aromatic ring or ring system (i.e., two or more fused rings sharing two adjacent atoms) that contains one or more heteroatoms, i.e., elements other than carbon, including, but not limited to, nitrogen, oxygen, and sulfur in the ring backbone. When heteroaryl is a ring system, each ring in the system is aromatic. Heteroaryl groups may have a ring member count (i.e., the number of atoms that make up the ring backbone, including carbon atoms and heteroatoms) of 5 to 18, although this definition also covers occurrences of the term "heteroaryl" where no numerical range is specified. In some embodiments, heteroaryl groups have a ring member count of 5 to 10 or a ring member count of 5 to 7. Heteroaryl groups may be designated as "5-7 membered heteroaryl," "5-10 membered heteroaryl," or similar designations. Examples of heteroaryl rings include, but are not limited to, furyl, thienyl, phthalazinyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, triazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, indolyl, isoindolyl, and benzothienyl.
[0056] A "heteroaralkyl" or "heteroarylalkyl" is a heteroaryl group bonded, as a substituent, via an alkylene group. Examples include, but are not limited to, 2-thienylmethyl, 3-thienylmethyl, furylmethyl, thienylethyl, pyrrolylalkyl, pyridylalkyl, isoxazolylalkyl, and imidazolylalkyl. In some cases, an alkylene group may be joined to a lower alkylene group (i.e., C 1-6 alkylene group).
[0057] As used herein, "carbocyclyl" means a non-aromatic cyclic ring or ring system containing only carbon atoms in the ring system backbone. When a carbocyclyl is a ring system, two or more rings may be joined together in a fused, bridged, or spiro-connected fashion. A carbocyclyl may have any degree of saturation, so long as at least one ring of the ring system is not aromatic. Thus, carbocyclyl includes cycloalkyl, cycloalkenyl, and cycloalkynyl. A carbocyclyl group may have 3 to 20 carbon atoms, although this definition also covers occurrences of the term "carbocyclyl" where no numerical range is specified. A carbocyclyl group may also be a medium-sized carbocyclyl having 3 to 10 carbon atoms. A carbocyclyl group may also be a carbocyclyl having 3 to 6 carbon atoms. A carbocyclyl group may also be designated as "C3-6 carbocyclyl" or similar designations. Examples of carbocyclyl rings include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, 2,3-dihydro-indene, bicycle[2.2.2]octanyl, adamantyl, and spiro[4.4]nonanyl.
[0058] As used herein, "cycloalkyl" means a fully saturated carbocyclyl ring or ring system. Examples include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
[0059] As used herein, "heterocyclyl" means a non-aromatic cyclic ring or ring system containing at least one heteroatom in the ring backbone. Heterocyclyls may be bonded together in a fused, bridged, or spiro-bonded manner. Heterocyclyls may have any degree of saturation, so long as at least one ring of the ring system is not aromatic. The heteroatoms may be present in either the non-aromatic or aromatic rings of the ring system. Heterocyclyl groups may have a ring member count (i.e., the number of atoms that make up the ring backbone, including carbon atoms and heteroatoms) of 3 to 20, although this definition also covers occurrences of the term "heterocyclyl" where no numerical range is specified. Heterocyclyl groups may also be medium-sized heterocyclyls having a ring member count of 3 to 10. Heterocyclyl groups may also be heterocyclyls having a ring member count of 3 to 6. Heterocyclyl groups may be designated as "3-6 membered heterocyclyl" or similar designations. In preferred 6-membered monocyclic heterocyclyls, the heteroatoms are selected from one to three of O, N, or S, and in preferred 5-membered monocyclic heterocyclyls, the heteroatoms are selected from one or two of O, N, or S heteroatoms.Examples of heterocyclyl rings include azepinyl, acridinyl, carbazolyl, cinnolinyl, dioxolanyl, imidazolinyl, imidazolidinyl, morpholinyl, oxiranyl, oxepanyl, thiepanyl, piperidinyl, piperazinyl, dioxopiperazinyl, pyrrolidinyl, 4-piperidonyl, pyrazolinyl, pyrazolidinyl, 1,3-dioxinyl, 1,3-dioxanyl, 1,4-dioxinyl, 1,4-dioxanyl, 1,3-oxathiyl, 1,4-oxathiinyl, 1,4-oxathiyl, 2H-1,2-oxazinyl, trioxanyl, hexahydro-1,3,5-triazinyl, and 1,3,5-triazinyl. These include, but are not limited to, diphenyl, 1,3-dioxolyl, 1,3-dioxolanyl, 1,3-dithiolyl, 1,3-dithiolanyl, isoxazolinyl, isoxazolidinyl, oxazolinyl, oxazolidinyl, oxazolidinonyl, thiazolinyl, thiazolidinyl, 1,3-oxathiolanyl, indolinyl, isoindolinyl, tetrahydrofuran, tetrahydropyranyl, tetrahydroiophenyl, tetrahydrothiopyranyl, tetrahydro-1,4-thiazinyl, thiamorpholinyl, dihydrobenzofuranyl, benzimidazolidinyl, and tetrahydroquinoline.
[0060] An "O-carboxy" group refers to a group in which R is hydrogen, C, as defined herein, 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Carbocyclyl, C 6-10 It refers to the group "--OC(.dbd.O)R" selected from aryl, 5-10 membered heteroaryl, and 3-10 membered heterocyclyl.
[0061] A "C-carboxy" group refers to a group in which R is hydrogen, C, as defined herein, 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Carbocyclyl, C 6-10"C(=O)OR" refers to a group selected from the group consisting of aryl, 5-10 membered heteroaryl, and 3-10 membered heterocyclyl. Non-limiting examples include carboxyl (i.e., -C(=O)OH).
[0062] A "sulfonyl" group is a group in which R is hydrogen, C, 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C3-7 carbocyclyl, C 6-10 Refers to a "-SO2R" group selected from aryl, 5-10 membered heteroaryl, and 3-10 membered heterocyclyl.
[0063] A "sulfino" group refers to a "-S(=O)OH" group.
[0064] An "S-sulfonamide" group is R A and R B are each independently hydrogen, as defined herein, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Carbocyclyl, C 6-10 aryl, 5- to 10-membered heteroaryl, and 3- to 10-membered heterocyclyl; A R B " group.
[0065] An "N-sulfonamide" group is R A and R B are each independently hydrogen, as defined herein, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Carbocyclyl, C 6-10 aryl, 5-10 membered heteroaryl, and 3-10 membered heterocyclyl; A )SO2R B " group.
[0066] A "C-amide" group is a group consisting of R A and RB are each independently hydrogen, as defined herein, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Carbocyclyl, C 6-10 aryl, 5-10 membered heteroaryl, and 3-10 membered heterocyclyl; A R B " group.
[0067] An "N-amide" group is R A and R B are each independently hydrogen, as defined herein, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Carbocyclyl, C 6-10 aryl, 5-10 membered heteroaryl, and 3-10 membered heterocyclyl; A )C(=O)R B " group.
[0068] An "amino" group is R A and R B are each independently hydrogen, as defined herein, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Carbocyclyl, C 6-10 aryl, 5- to 10-membered heteroaryl, and 3- to 10-membered heterocyclyl; A R B " group. Non-limiting examples include free amino (i.e., --NH2).
[0069] An "aminoalkyl" group refers to an amino group connected via an alkylene group.
[0070] The "alkoxyalkyl" group is defined as "C 2-8 "Alkoxyalkyl" refers to an alkoxy group bonded via an alkylene group, such as "alkoxyalkyl" or "alkoxyalkyl."
[0071] As used herein, a substituent is derived from an unsubstituted parent group in which one or more hydrogen atoms have been replaced with another atom or group. Unless otherwise specified, when a group is considered to be "substituted", the group includes C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkynyl, C1-C6 heteroalkyl, C3-C7 carbocyclyl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, and C1-C6 haloalkoxy), C3-C7-carbocyclyl-C1-C6-alkyl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, and C1-C6 haloalkoxy), 3- 10-membered heterocyclyl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, and C1-C6 haloalkoxy), 3-10-membered heterocyclyl-C1-C6-alkyl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, and C1-C6 haloalkoxy), aryl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, and C1-C6 haloalkoxy), aryl(C1-C6)alkyl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, and C1-C6 haloalkoxy), substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, and C1-C6 haloalkoxy); 5-10 membered heteroaryl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, and C1-C6 haloalkoxy); 5-10 membered heteroaryl(C1-C6)alkyl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, and C1-C6 haloalkoxy); halo, -CN, hydroxy, C1-C6 alkoxy, C 1-C6 alkoxy(C1-C6)alkyl (i.e., ether), aryloxy, sulfhydryl (mercapto), halo(C1-C6)alkyl (e.g., -CF3), halo(C1-C6)alkoxy (e.g., -OCF3), C1-C6 alkylthio, arylthio, amino, amino(C1-C6)alkyl, nitro, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carboxy, O-carboxy, acyl, cyanato,It means substituted with one or more substituents independently selected from isocyanato, thiocyanato, isothiocyanato, sulfinyl, sulfonyl, -SO3H, sulfino, -OSO2C1-4 alkyl, and oxo (=O). Whenever a group is described as "optionally substituted," that group can be substituted with the above-listed substituents.
[0072] In some embodiments, the substituted alkyl, alkenyl, or alkynyl group is selected from halo, -CN, SO3 - , -SO3H, -SR A , -OR A , -NR B R C , oxo, -CONR B R C , -SO2NR B R C , -COOH, and -COOR B and R is substituted with one or more substituents selected from the group consisting of A , R B , and R C are each independently selected from H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, and substituted aryl.
[0073] The compounds described herein can be represented in several mesomeric forms. When a single structure is depicted, any of the related mesomeric forms are intended. The coumarin compounds described herein are represented by a single structure, but can equally be represented in any of the related mesomeric forms. An exemplary mesomeric structure for formula (I) is shown below: [ka]
[0074] In each instance where a single mesomeric form of a compound described herein is shown, the alternative mesomeric form is equally contemplated.
[0075] As will be appreciated by those of skill in the art, the compounds described herein may exist in ionized form, e.g., -CO2- or -SO3-. If the compound contains a positively or negatively charged substituent, e.g., SO3 - It may also include a negatively or positively charged counterion, such that the compound is overall neutral. In other aspects, the compound may exist in the form of a salt, where the counterion is provided by a conjugate acid or base.
[0076] It is understood that certain radical naming conventions can include either monoradicals or diradicals, depending on the context. For example, if a substituent requires two points of attachment to the remainder of the molecule, the substituent is understood to be a diradical. For example, a substituent identified as an alkyl, which requires two points of attachment, includes diradicals such as -CH2-, -CH2CH2-, -CH2CH(CH3)CH2-, etc. Other radical naming conventions clearly indicate that the radical is a diradical, such as "alkylene" or "alkenylene."
[0077] When two "adjacent" R groups are said to form a ring "together with the atoms to which they are attached," it is meant that the collective unit of atoms, the intervening bond, and the two R groups is the depicted ring. For example, the following substructure exists: [ka] And R 1 and R 2 is defined as being selected from the group consisting of hydrogen and alkyl, or R 1 and R 2 are defined as forming an aryl or carbocyclyl together with the atom to which they are attached, R 1 and R 2 may be selected from hydrogen or alkyl, or the substructure has the structure: [ka] wherein A is an aryl ring or carbocyclyl containing the depicted double bond.
[0078] (Labeled Nucleotides) According to one aspect of the present disclosure, dye compounds suitable for binding to substrate moieties are provided, particularly dye compounds that include a linker group that allows binding to substrate moieties. Substrate moieties can be virtually any molecule or substance to which the dyes of the present disclosure can be conjugated, and non-limiting examples can include nucleosides, nucleotides, polynucleotides, carbohydrates, ligands, particles, solid surfaces, organic and inorganic polymers, chromosomes, nuclei, living cells, and combinations or assemblies thereof. The dyes can be conjugated by various means, such as hydrophobic attraction, ionic attraction, covalent binding, and the like, with an optional linker. In some aspects, the dyes are conjugated to the substrate by covalent binding. More specifically, the covalent binding is through a linker group. In some cases, such labeled nucleotides are also referred to as "modified nucleotides".
[0079] The present disclosure further provides conjugates of nucleosides and nucleotides (modified nucleotides) labeled with one or more dyes described herein. The labeled nucleosides and nucleotides are useful for labeling polynucleotides formed by enzymatic synthesis, such as, by way of non-limiting example, PCR amplification, isothermal amplification, solid-phase amplification, polynucleotide sequencing (e.g., solid-phase sequencing), nick translation reactions, and the like.
[0080] The binding to the biomolecule is carried out by the R, R 1 , R 2 , R 3 , R 4 , R 5 , or X position. In some embodiments, the connection may be via the R 3 or R 5Through a group. In some embodiments, the substituent is carboxyl or substituted alkyl, such as alkyl substituted with -CO2H, or an activated form of the carboxyl group, such as an amide or ester, which can be used to bind to amino or hydroxyl groups of biomolecules. As used herein, the term "activated ester" refers to a carboxyl group derivative that can react under mild conditions, for example, with a compound that contains an amino group. Non-limiting examples of activated esters include, but are not limited to, p-nitrophenyl, pentafluorophenyl, and succinimide esters.
[0081] In some embodiments, dye compounds can be covalently linked to oligonucleotides or nucleotides via nucleotide bases.For example, labeled nucleotides or oligonucleotides can have labels linked to the C5 position of pyrimidine bases or the C7 position of 7-deazapurine bases via linker moieties.Labeled nucleotides or oligonucleotides can also have 3'-OH blocking groups covalently linked to the ribose or deoxyribose sugars of nucleotides.
[0082] A particularly useful application of the novel fluorescent dyes as described herein is to label biomolecules, such as nucleotides or oligonucleotides. Some embodiments of the present application relate to nucleotides or oligonucleotides labeled with the novel fluorescent compounds as described herein.
[0083] (Linker) The dye compounds disclosed herein may include a reactive linker group at one of the substituent positions for covalent attachment of the compound to a substrate or another molecule. A reactive linking group is a moiety capable of forming a bond (e.g., covalent or non-covalent), especially a covalent bond. In a particular embodiment, the linker may be a cleavable linker. The use of the term "cleavable linker" does not imply that the entire linker needs to be removed. The cleavage site can be located at a position on the linker that ensures that a portion of the linker remains attached to the dye and / or substrate moiety after cleavage. The cleavable linker may be, by way of non-limiting examples, an electrophilically cleavable linker, a nucleophilically cleavable linker, a photocleavable linker, cleavable under reductive conditions (e.g., disulfide or azide-containing linkers), oxidative conditions, cleavable through the use of a safety catch linker, or cleavable by an exclusion mechanism. Using a cleavable linker to attach the dye compound to the substrate moiety allows for the label to be removed after detection, if desired, to avoid interfering signals in downstream steps.
[0084] Useful linker groups can be found in PCT Publication No. WO 2004 / 018493 (herein incorporated by reference), examples of which include the linker that can be cleaved using a water-soluble phosphine or water-soluble transition metal catalyst formed from a transition metal and at least partially water-soluble ligand. In aqueous solution, the latter forms at least partially water-soluble transition metal complex. Such cleavable linkers can be used to connect the base of nucleotide to a label, such as the dye described herein.
[0085] Particular linkers include those disclosed in PCT Publication No. WO 2004 / 018493 (herein incorporated by reference), such as those that include a moiety of the following formula: [ka] wherein X is selected from the group including O, S, NH, and NQ, Q is a C1-10 substituted or unsubstituted alkyl group, Y is selected from the group including O, S, NH, and N(aryl), and T is hydrogen or a C1-C 10 (A linker is a substituted or unsubstituted alkyl group, and * indicates where the moiety is attached to the remainder of the nucleotide or nucleoside.) In some embodiments, the linker connects the base of the nucleotide to a label, such as, for example, a dye compound described herein.
[0086] Additional examples of linkers include those disclosed in U.S. Publication Nos. 2016 / 0040225 and 2019 / 0017111 (herein incorporated by reference), such as those that include a moiety of the following formula: [ka] The linker moieties referred to herein may include all or part of the linker structure between the nucleotide / nucleoside and the label.
[0087] In particular embodiments, the length of the linker between the fluorescent dye (fluorophore) and the guanine base can be modified, for example by introducing a polyethylene glycol spacer group, thereby increasing the fluorescence intensity compared to the same fluorophore attached to the guanine base via other linkages known in the art. Exemplary linkers and their properties are shown in PCT Publication No. WO 2007020457, which is incorporated herein by reference. The design of the linkers, particularly their increased length, can improve the brightness of the fluorophore attached to the guanine base of a guanosine nucleotide when incorporated into a polynucleotide such as DNA. Thus, when the dye is used in an analytical method requiring the detection of a fluorescent dye label attached to a guanine-containing nucleotide, the linker can be of the formula -((CH2)2O) n Advantageously, it comprises a spacer group of the formula -, where n is an integer between 2 and 50.
[0088] Nucleosides and nucleotides can be labeled at sites on the sugar or nucleobase. As known in the art, a "nucleotide" consists of a nitrogenous base, a sugar, and one or more phosphate groups. In RNA, the sugar is ribose, and in DNA, it is deoxyribose, i.e., a sugar lacking the hydroxyl group present in ribose. The nitrogenous bases are derivatives of purines or pyrimidines. Purines are adenine (A) and guanine (G), and pyrimidines are cytosine (C) and thymine (T), or, in the context of RNA, uracil (U). The C-1 atom of the deoxyribose is attached to the N-1 of the pyrimidine or the N-9 of the purine. Nucleotides are also phosphate esters of nucleosides, with esterification occurring at the hydroxyl group attached to the C-3 or C-5 of the sugar. Nucleotides are usually mono-, di-, or triphosphates.
[0089] A "nucleoside" is structurally similar to a nucleotide, but lacks the phosphate moiety. An example of a nucleoside analog would be one in which the label is linked to the base and there is no phosphate group attached to the sugar molecule.
[0090] Although the bases are usually referred to as purines or pyrimidines, one skilled in the art will understand that derivatives and analogs are available that do not change the ability of the nucleotide or nucleoside to undergo Watson-Crick base pairing. By "derivative" or "analog" is meant a compound or molecule whose core structure is the same as or very similar to the parent compound, but which has chemical or physical modifications, e.g., different or additional side chains, that allow the derivative nucleotide or nucleoside to be attached to another molecule. For example, the base may be a deazapurine. In particular embodiments, the derivative should be capable of undergoing Watson-Crick pairing. "Derivative" and "analog" also include, for example, synthetic nucleotide or nucleoside derivatives with modified base moieties and / or modified sugar moieties. Such derivatives and analogs are discussed, for example, in Scheit, Nucleotide analogs (John Wiley & Son, 1980) and Uhlman et al., Chemical Reviews 90:543-584, 1990. Nucleotide analogs may also contain modified phosphodiester linkages, including phosphorothioate, phosphorodithioate, alkylphosphonate, phosphoranilidate, phosphoramidate linkages, and the like.
[0091] The dye can be attached to any position on the nucleotide base, for example, via a linker. In a particular embodiment, Watson-Crick base pairing can still be performed on the resulting analog. Particular nucleobase labeling sites include the C5 position of pyrimidine bases or the C7 position of 7-deazapurine bases. As mentioned above, the dye can be covalently attached to the nucleoside or nucleotide using a linker group.
[0092] In particular embodiments, the labeled nucleoside or nucleotide can be enzymatically incorporated and enzymatically extendable. Thus, the linker portion can be long enough to connect the nucleotide to the compound so that the compound does not significantly interfere with the overall binding and recognition of the nucleotide by the nucleic acid replicating enzyme. Thus, the linker can also include a spacer unit. The spacer separates the nucleotide base from, for example, the cleavage site or the label.
[0093] A nucleoside or nucleotide labeled with the dyes described herein may have the formula: [ka] where Dye is a dye compound; B is a nucleobase, e.g., uracil, thymine, cytosine, adenine, guanine; L is an optional linker group that may or may not be present; R' can be H, monophosphate, diphosphate, triphosphate, thiophosphate, phosphate ester analogs, -O- attached to a reactive phosphorus-containing group, or -O- protected by a blocking group; R'' is H, OH, a phosphoramidite, or a 3'-OH blocking group, and R''' is H or OH. When R'' is a phosphoramidite, R' is an acid-cleavable hydroxyl protecting group, allowing for subsequent monomer coupling under automated synthesis conditions.
[0094] In particular embodiments, the blocking group is separate and independent from the dye compound, i.e., not attached thereto. Alternatively, the dye may include all or a portion of the 3'-OH blocking group. Thus, R'' may be a 3'-OH blocking group that may or may not include a dye compound.
[0095] In yet another alternative embodiment, there is no blocking group on the 3' carbon of the pentose sugar, for example, the dye attached to the base (or the dye and linker construct) may be of sufficient size or structure to act as a block to the incorporation of additional nucleotides. Thus, blocking may be due to steric hindrance, or due to a combination of size, charge, and structure, regardless of whether the dye is attached to the 3' position of the sugar.
[0096] In yet another alternative embodiment, the blocking group may be present on the 2' or 4' carbon of the pentose sugar and may be of sufficient size or structure to act as a block to the incorporation of additional nucleotides.
[0097] The use of blocking groups allows for the control of polymerization, such as by terminating elongation when a modified nucleotide is incorporated. If the blocking effect is reversible, elongation can be stopped at a particular time point and then continued, for example, by changing the chemical conditions or removing the chemical block, but not by way of limiting example.
[0098] In another particular embodiment, the 3'-OH blocking group will include the moieties disclosed in WO 2004 / 018497 and WO 2014 / 139569, which are incorporated herein by reference. For example, the blocking group can be azidomethyl (-CH2N3) or substituted azidomethyl (e.g., -CH(CHF2)N3 or CH(CH2F)N3), or allyl.
[0099] In particular embodiments, the linker (between the dye and the nucleotide) and the blocking group are both present and are separate moieties. In particular embodiments, the linker and the blocking group are both cleavable under substantially similar conditions. Thus, the deprotection and deblocking process may be more efficient, since only one treatment is required to remove both the dye compound and the blocking group. However, in some embodiments, the linker and the blocking group do not need to be cleavable under similar conditions, but instead are individually cleavable under separate conditions.
[0100] The present disclosure also encompasses polynucleotides incorporating dye compounds. Such polynucleotides may be DNA or RNA, each composed of deoxyribonucleotides or ribonucleotides linked by phosphodiester bonds. Polynucleotides may contain naturally occurring nucleotides, non-naturally occurring (or modified) nucleotides other than the labeled nucleotides described herein, or any combination thereof, in combination with at least one modified nucleotide (e.g., labeled with a dye compound) as described herein. Polynucleotides according to the present disclosure may also contain non-natural backbone bonds and / or non-nucleotide chemical modifications. Chimeric structures composed of a mixture of ribonucleotides and deoxyribonucleotides containing at least one labeled nucleotide are also contemplated.
[0101] Non-limiting exemplary labeled nucleotides described herein include: [ka] In the formula, L represents a linker and R represents a sugar residue as described above.
[0102] In some embodiments, non-limiting exemplary fluorescent dye conjugates are shown below: [ka]
[0103] (kit) The present disclosure also provides a kit that includes modified nucleosides and / or dye-labeled nucleotides.Such kits will generally include at least one modified nucleotide or nucleoside labeled with dyes as described herein, together with at least one additional component.The additional component may be one or more components that are specified in the methods described herein or in the methods described in the Examples section below.Some non-limiting examples of components that can be combined into the kit of the present disclosure are described below.
[0104] In particular embodiments, the kit can include at least one modified nucleotide or nucleoside labeled with a dye as described herein, along with modified or unmodified nucleotides or nucleosides. For example, modified nucleotides labeled with dyes according to the present disclosure can be provided in combination with unlabeled or natural nucleotides and / or in combination with fluorescently labeled nucleotides or any combination thereof. Thus, the kit can include modified nucleotides labeled with dyes according to the present disclosure and other modified nucleotides labeled with, for example, prior art dye compounds. The combination of nucleotides can be provided as separate individual components (e.g., one nucleotide type per container or tube) or as a nucleotide mixture (e.g., two or more nucleotides mixed in the same container or tube).
[0105] When the kit includes multiple, particularly two, or three, or more particularly four modified nucleotides labeled with dye compounds, the different nucleotides may be labeled with different dye compounds, or one may be dark, without dye compounds. When the different nucleotides are labeled with different dye compounds, it is a feature of the kit that the dye compounds are spectrally distinguishable fluorescent dyes. As used herein, the term "spectrally distinguishable fluorescent dyes" refers to fluorescent dyes that emit fluorescent energy at wavelengths that can be distinguished by a fluorescent detection device (e.g., a commercially available capillary-based DNA sequencing platform) when two or more such dyes are present in a sample. When two modified nucleotides labeled with fluorescent dye compounds are provided in the form of a kit, it is a feature of some embodiments that the spectrally distinguishable fluorescent dyes can be excited at the same wavelength, for example, by the same laser. When four modified nucleotides labeled with fluorescent dye compounds are provided in the form of a kit, it is a feature of some embodiments that two of the spectrally distinguishable fluorescent dyes are both excited at one wavelength, and the other two spectrally distinguishable dyes are both excited at another wavelength. Specific excitation wavelengths are 488 nm and 532 nm.
[0106] In one embodiment, the kit includes a modified nucleotide labeled with a compound of the present disclosure and a second modified nucleotide labeled with a second dye, where the dyes have a difference in maximum absorbance of at least 10 nm, particularly 20 nm to 50 nm. More specifically, the two dye compounds have a Stokes shift of 15 to 40 nm, the "Stokes shift" being the distance between the peak absorption wavelength and the peak emission wavelength.
[0107] In further embodiments, the kit may further comprise two other modified nucleotides labeled with fluorescent dyes, the dyes being excited by the same laser at 532 nm. The dyes may have a difference in maximum absorbance of at least 10 nm, particularly 20 nm to 50 nm. More particularly, the two dye compounds may have a Stokes shift between 20 and 40 nm. Particular dyes that are spectrally distinguishable from the dyes of the present disclosure and meet the above criteria are polymethine analogs such as those described in U.S. Pat. No. 5,268,486 (e.g., Cy3) or WO 0226891 (Alexa 532; Molecular Probes A20106), or asymmetric polymethines as disclosed in U.S. Pat. No. 6,924,372, each of which is incorporated herein by reference. Alternative dyes include rhodamine analogs, such as tetramethylrhodamine and its analogs.
[0108] In an alternative embodiment, the kit of the present disclosure may include nucleotides in which the same base is labeled with two different compounds. The first nucleotide may be labeled with a compound of the present disclosure. The second nucleotide may be labeled with a spectrally distinct compound, such as a "green" dye that absorbs below 600 nm. The third nucleotide may be labeled as a mixture of a compound of the present disclosure and a spectrally distinct compound, and the fourth nucleotide may be "dark" and unlabeled. Thus, in brief, nucleotides 1-4 may be labeled "blue", "green", "blue / green", and dark. To further simplify the instrumentation, the four nucleotides may be labeled with two dyes excited by a single laser, and thus the labels of nucleotides 1-4 may be "blue 1", "blue 2", "blue 1 / blue 2", and dark.
[0109] The nucleotide may include two dyes of the present disclosure. The kit may include two or more nucleotides labeled with a dye of the present disclosure. The kit may include another nucleotide, where the nucleotide is labeled with a dye that absorbs in the range of 520 nm to 560 nm. The kit may further include an unlabeled nucleotide.
[0110] Although the kits are exemplified herein in a configuration having different nucleotides labeled with different dye compounds, it will be understood that the kits may contain two, three, four or more different nucleotides having the same dye compound.
[0111] In particular embodiments, the kit may include a polymerase enzyme capable of catalyzing the incorporation of modified nucleotides into a polynucleotide. Other components included in such kits may include buffers, etc. The modified nucleotides labeled with dyes according to the present disclosure, and any other nucleotide components, including mixtures of different nucleotides, may be provided in the kit in a concentrated form that is diluted before use. In such embodiments, a suitable dilution buffer may also be included. Again, one or more components identified in the methods described herein may be included in the kit of the present disclosure.
[0112] (Sequencing Method) The modified nucleotide (or nucleoside) comprising the dye compound according to the present disclosure, whether by itself or incorporated or associated with a larger molecular structure or conjugate, may be used in any analytical method, such as a method involving detection of a fluorescent label attached to the nucleotide or nucleoside. In this context, the term "incorporated into a polynucleotide" may mean that the 5' phosphate is attached to the 3' hydroxyl group of a second (modified or unmodified) nucleotide in a phosphodiester bond, and itself may form part of a longer polynucleotide chain. The 3' end of the modified nucleotide described herein may or may not be attached to the 5' phosphate of an additional (modified or unmodified) nucleotide in a phosphodiester bond. Thus, in one non-limiting embodiment, the present disclosure provides a method for detecting a modified nucleotide incorporated into a polynucleotide, comprising: (a) incorporating at least one modified nucleotide of the present disclosure into a polynucleotide, and (b) detecting the modified nucleotide incorporated into a polynucleotide by detecting a fluorescent signal from a dye compound attached to said modified nucleotide.
[0113] The method may include: a synthesis step (a), in which one or more modified nucleotides according to the present disclosure are incorporated into a polynucleotide, and a detection step (b), in which the one or more modified nucleotides incorporated into the polynucleotide are detected by detecting or quantitatively measuring their fluorescence.
[0114] Some embodiments of the present application are directed to a method of sequencing comprising: (a) incorporating at least one labeled nucleotide as described herein into a polynucleotide; and (b) detecting the labeled nucleotide incorporated into the polynucleotide by detecting a fluorescent signal from a novel fluorescent dye attached to the modified nucleotide.
[0115] In one embodiment, at least one modified nucleotide is incorporated into polynucleotide at the synthesis stage by the action of polymerase enzyme.However, other methods can be used to attach modified nucleotide to polynucleotide, such as, for example, chemical oligonucleotide synthesis or ligation of labeled oligonucleotide to unlabeled oligonucleotide.Therefore, the term "incorporating" when used in relation to nucleotide and polynucleotide can include chemical and enzymatic polynucleotide synthesis.
[0116] In a specific embodiment, the synthesis step is carried out and may optionally include incubating the template polynucleotide strand with a reaction mixture that includes the fluorescently labeled modified nucleotide of the present disclosure. A polymerase may also be provided under conditions that allow the formation of a phosphodiester bond between the free 3' hydroxyl group on the polynucleotide strand annealed to the template polynucleotide strand and the 5' phosphate group on the modified nucleotide. Thus, the synthesis step may include the formation of a polynucleotide strand as directed by the complementary base pairing of nucleotides to the template strand.
[0117] In all embodiments of the method, the detection step may be carried out while the polynucleotide strand into which the labeled nucleotide is incorporated is annealed to the template strand, or after the denaturation step in which the two strands are separated. Further steps, such as chemical or enzymatic reaction steps or purification steps, may be included between the synthesis step and the detection step. In particular, the target strand incorporating the labeled nucleotide may be isolated or purified and then further processed or used in a subsequent analysis. As an example, the target polynucleotide labeled with modified nucleotides as described herein in the synthesis step may be subsequently used as a labeled probe or primer. In other embodiments, the products of the synthesis steps described herein may be subjected to further reaction steps, and if necessary, the products of these subsequent steps may be purified or isolated.
[0118] Suitable conditions for the synthesis step are well known to those familiar with standard molecular biology techniques. In one embodiment, the synthesis step may resemble a standard primer extension reaction that uses nucleotide precursors, including modified nucleotides as described herein, to form an extended target strand complementary to the template strand in the presence of a suitable polymerase enzyme. In other embodiments, the synthesis step itself may form part of an amplification reaction, generating a labeled double-stranded amplification product consisting of annealed complementary strands derived from copies of the target and template polynucleotide strands. Other exemplary synthesis steps include nick translation, strand displacement polymerization, random priming DNA labeling, and the like. Particularly useful polymerase enzymes for the synthesis step are those capable of catalyzing the incorporation of modified nucleotides as described herein. A variety of natural or modified polymerases may be used. By way of example, thermostable polymerases may be used for synthesis reactions carried out using thermocycling conditions, but thermostable polymerases may not be desirable for isothermal primer extension reactions. Suitable thermostable polymerases that can incorporate modified nucleotides according to the present disclosure include those described in WO 2005 / 024010 or WO 06120433, each of which is incorporated herein by reference. For synthesis reactions carried out at low temperatures, such as 37° C., the polymerase enzyme does not necessarily need to be a thermostable polymerase, and therefore the choice of polymerase will depend on many factors, such as reaction temperature, pH, strand displacement activity, etc.
[0119] In certain non-limiting embodiments, the present disclosure encompasses methods for nucleic acid sequencing, resequencing, whole genome sequencing, single nucleotide polymorphism scoring, and any other application involving detection of modified nucleotides or nucleosides labeled with the dyes described herein when incorporated into a polynucleotide. Any of a variety of other applications that benefit from the use of polynucleotides labeled with modified nucleotides containing fluorescent dyes can use modified nucleotides or nucleosides bearing the dyes described herein.
[0120] In a particular embodiment, the present disclosure provides the use of modified nucleotides comprising dye compounds according to the present disclosure in polynucleotide sequencing by synthesis reactions. Sequencing by synthesis generally involves sequentially adding one or more nucleotides or oligonucleotides to a growing polynucleotide chain in a 5' to 3' direction using a polymerase or ligase to form an extended polynucleotide chain complementary to a template nucleic acid for sequencing. The identity of the base present in one or more of the added nucleotides can be determined in a detection or "imaging" step. The identity of the added base may be determined after each nucleotide incorporation step. The sequence of the template may then be inferred using conventional Watson-Crick base pairing rules. The use of modified nucleotides labeled with dyes described herein to determine the identity of a single base may be useful, for example, in scoring single nucleotide polymorphisms, and such single base extension reactions are within the scope of the present disclosure.
[0121] In one embodiment of the present disclosure, The sequence of a template polynucleotide is determined by detecting the incorporation of one or more nucleotides into a nascent strand complementary to the template polynucleotide to be sequenced through detection of a fluorescent label attached to the incorporated nucleotide. Sequencing of the template polynucleotide can be primed with an appropriate primer (or can be prepared as a hairpin construct that includes a primer as part of the hairpin), The nascent strand is extended stepwise by adding nucleotides to the 3' end of the primer in a polymerase-catalyzed reaction.
[0122] In a particular embodiment, each of the different nucleotide triphosphates (A, T, G and C) may be labeled with a unique fluorophore and also contain a blocking group at the 3' position to prevent uncontrolled polymerization. Alternatively, one of the four nucleotides may be unlabeled (dark). The polymerase enzyme incorporates the nucleotide into the nascent strand complementary to the template polynucleotide, and the blocking group prevents further incorporation of the nucleotide. Unincorporated nucleotides can be washed away, and the fluorescent signal from each incorporated nucleotide can be optically "read" by appropriate means, such as a charge-coupled device using laser excitation and appropriate emission filters. The 3'-blocking group and the fluorochrome compound can then be removed (deprotected) (simultaneously or sequentially) to expose the nascent strand for further incorporation of nucleotides. Typically, the identity of the incorporated nucleotide is determined after each incorporation step, although this is not strictly required. Similarly, U.S. Pat. No. 5,302,509 (incorporated herein by reference) discloses a method for sequencing polynucleotides immobilized on a solid support.
[0123] As exemplified above, this method utilizes the incorporation of fluorescently labeled 3' blocked nucleotides A, G, C, and T into a growing strand complementary to an immobilized polynucleotide in the presence of a DNA polymerase. The polymerase incorporates the base complementary to the target polynucleotide, but further addition is prevented by the 3' blocking group. The label of the incorporated nucleotide can then be determined, and the blocking group can be removed by chemical cleavage to allow further polymerization to occur. The nucleic acid template to be sequenced in the sequencing by synthesis reaction can be any polynucleotide that one desires to sequence. The nucleic acid template for the sequencing reaction will typically include a double-stranded region with a free 3' hydroxyl group that serves as a primer or starting point for the addition of additional nucleotides in the sequencing reaction. The region of the template to be sequenced will overhang this free 3' hydroxyl group on the complementary strand. The overhanging region of the template to be sequenced may be single-stranded, but is double-stranded, provided that a "nick" is present in the strand complementary to the template strand to be sequenced, providing a free 3'OH group for the initiation of the sequencing reaction. In such an embodiment, sequencing may proceed by strand displacement. In a particular embodiment, a primer with a free 3' hydroxyl group may be added as a separate component (e.g., a short oligonucleotide) that hybridizes to the single-stranded region of the template to be sequenced. Alternatively, the primer and template strand to be sequenced may each form part of a partially self-complementary nucleic acid strand that can form an intramolecular duplex, such as a hairpin loop structure. Hairpin polynucleotides and methods by which they can be attached to solid supports are disclosed in PCT Publication Nos. WO 0157248 and WO 2005 / 047301, each of which is incorporated herein by reference. Nucleotides may be added sequentially to the growing primer, resulting in the synthesis of a polynucleotide strand in the 5' to 3' direction.The nature of the added base can, inter alia, be determined after each nucleotide addition, although not necessarily, thus providing sequence information of the nucleic acid template.Thus, nucleotides are incorporated into a nucleic acid strand (or polynucleotide) by linking the nucleotide to the free 3' hydroxyl group of the nucleic acid strand through formation of a phosphodiester bond with the 5' phosphate group of the nucleotide.
[0124] The nucleic acid template to be sequenced may be DNA or RNA, or even a hybrid molecule consisting of deoxynucleotides and ribonucleotides. The nucleic acid template may contain naturally occurring and / or non-naturally occurring nucleotides and natural or non-natural backbone bonds, provided that these do not interfere with the copying of the template in the sequencing reaction.
[0125] In particular embodiments, the nucleic acid template to be sequenced may be attached to the solid support via any suitable attachment method known in the art, for example, via covalent attachment. In particular embodiments, the template polynucleotide may be directly attached to the solid support (e.g., a silica-based support). However, in other embodiments of the present disclosure, the surface of the solid support may be modified in some way to allow direct covalent attachment of the template polynucleotide or to immobilize the template polynucleotide via a hydrogel or polyelectrolyte multilayer that may itself be non-covalently attached to the solid support.
[0126] Arrays in which polynucleotides are directly attached to silica-based supports are, for example, those disclosed in WO 00006770 (incorporated herein by reference), in which polynucleotides are immobilized on glass supports by reaction between pendant epoxide groups on glass and internal amino groups. For polynucleotides. In addition, polynucleotides can be attached to solid supports by reaction of sulfur-based nucleophiles with solid supports, for example, as described in WO 2005 / 047301 (incorporated herein by reference). Yet another example of solid-supported template polynucleotides is when template polynucleotides are attached to hydrogels supported on silica-based or other solid supports, for example, as described in WO 00 / 31148, WO 01 / 01143, WO 02 / 12566, WO 03 / 014392, U.S. Patent No. 6,465,178 and WO 00 / 53812 (each of which is incorporated herein by reference).
[0127] A specific surface that can immobilize template polynucleotide is polyacrylamide hydrogel.Polyacrylamide hydrogel is described in the references cited above and WO2005 / 065814, which is incorporated herein by reference.Specific hydrogels that can be used include those described in WO2005 / 065814 and US Publication No. 2014 / 0079923.In one embodiment, the hydrogel is PAZAM (poly(N-(5-azidoacetamidylpentyl)acrylamide-co-acrylamide)).
[0128] DNA template molecules can be bound to beads or microparticles, for example, as described in U.S. Patent No. 5,419,096. U.S. Patent No. 6,172,218 (hereby incorporated by reference). Binding to beads or microparticles can be useful for sequencing applications. Bead libraries can be prepared where each bead contains a different DNA sequence. Exemplary libraries and methods for making them are described in Nature, 437, 376-380 (2005); Science, 309, 5741, 1728-1732 (2005), each of which is hereby incorporated by reference. Sequencing such arrays of beads using nucleotides as described herein is within the scope of this disclosure.
[0129] The template to be sequenced may form part of an "array" on a solid support, where the array may take any convenient form.Thus, the method of the present disclosure is applicable to all types of high-density arrays, including single molecule arrays, clustered arrays, and bead arrays.The modified nucleotides labeled with the dye compounds of the present disclosure may be used to sequence the templates on essentially any type of array, including but not limited to those formed by immobilizing nucleic acid molecules on a solid support.
[0130] However, modified nucleotides labeled with dye compounds of the present disclosure are particularly advantageous in the context of clustered array sequencing. In clustered arrays, distinct regions (often called sites or features) on the array contain multiple polynucleotide template molecules. Generally, the multiple polynucleotide molecules are not individually resolvable by optical means, but are instead detected as an ensemble. Depending on how the array is formed, each site on the array may contain multiple copies of one individual polynucleotide molecule (e.g., the site is homogenous to a particular single-stranded or double-stranded nucleic acid species), or multiple copies of a small number of different polynucleotide molecules (e.g., multiple copies of two different nucleic acid species). Clustered arrays of nucleic acid molecules may be generated using techniques commonly known in the art. By way of example, WO 98 / 44151 and WO 00 / 18957, each of which is incorporated herein, describe methods of amplifying nucleic acids in which both the template and the amplification products remain immobilized on a solid support to form an array composed of clusters or "colonies" of immobilized nucleic acid molecules. The nucleic acid molecules present on the clustered arrays prepared according to these methods are suitable templates for sequencing using modified nucleotides labeled with the dye compounds of the present disclosure.
[0131] Modified nucleotides labeled with the dye compounds of the present disclosure are also useful in sequencing templates on single molecule arrays. The term "single molecule array" or "SMA" as used herein refers to a population of polynucleotide molecules distributed (or arrayed) on a solid support, where the spacing of any individual polynucleotide from all others in the population is such that it is possible to individually separate the individual polynucleotide molecules. Thus, the target nucleic acid molecules immobilized on the surface of a solid support may, in some embodiments, be resolvable by optical means. This means that one or more distinct signals, each representing one polynucleotide, are generated within the resolvable area of the particular imaging device used.
[0132] Single molecule detection can be achieved with spacing between adjacent polynucleotide molecules on the array of at least 100 nm, more particularly at least 250 nm, even more particularly at least 300 nm, even more particularly at least 350 nm. Thus, each molecule can be individually resolved and detected as a single molecule fluorescent spot, and the fluorescence from said single molecule fluorescent spot also exhibits single-step photobleaching.
[0133] The terms "individually resolved" and "individually resolved" are used herein to specify that when visualized, it is possible to distinguish one molecule on the array from its neighboring molecules. The separation between individual molecules on the array is determined, in part, by the specific technique used to resolve the individual molecules. The general characteristics of single molecule arrays can be understood by referring to published applications WO 00 / 06770 and WO 01 / 57248, each of which is incorporated herein by reference. One use of the modified nucleotides of the present disclosure is a sequencing-by-synthesis reaction, although the utility of the modified nucleotides is not limited to such methods. Indeed, the nucleotides can be advantageously used in any sequencing methodology that requires the detection of a fluorescent label attached to a nucleotide incorporated into a polynucleotide.
[0134] In particular, modified nucleotides labeled with the dye compounds of the present disclosure may be used in automated fluorescent sequencing protocols, particularly fluorescent dye terminator cycle sequencing based on the chain termination sequencing method of Sanger and coworkers. Such methods generally incorporate fluorescently labeled dideoxynucleotides into primer extension sequencing reactions using enzymes and cycle sequencing. The so-called Sanger sequencing method and related protocols (Sanger-type) utilize randomized chain termination by labeled dideoxynucleotides.
[0135] Thus, the present disclosure also includes modified nucleotides labeled with dye compounds that are dideoxynucleotides lacking hydroxyl groups at both the 3' and 2' positions, such modified dideoxynucleotides being suitable for use in Sanger-type sequencing methods and the like.
[0136] Modified nucleotides labeled with the dye compounds of the present disclosure incorporating 3' blocking groups may also be useful in Sanger sequencing and related protocols, as will be appreciated, because the same effect achieved by using modified dideoxynucleotides can be achieved by using modified nucleotides with 3'-OH blocking groups: both prevent the incorporation of subsequent nucleotides.It will be understood that when nucleotides according to the present disclosure and with 3' blocking groups are used in Sanger-type sequencing, the dye compounds or detectable labels attached to the nucleotides do not need to be connected via cleavable linkers, because in each instance, when the labeled nucleotides of the present disclosure are incorporated; there is no need to subsequently incorporate nucleotides, and therefore no need to remove the label from the nucleotide. EXAMPLES
[0137] Additional embodiments are disclosed in further detail in the following examples, which are not intended to limit the scope of the claims in any way.
[0138] [Example 1: Compound I-1: 7-(3-carboxyazetidinyl-1)-3-(5-chloro-benzoxazol-2-yl)coumarin] [ka] 3-(5-Chloro-benzoxazol-2-yl)-7-fluoro-coumarin (0.32 g, 1 mmol) and 3-carboxyazetidine (0.2 g, 2 mmol) were added to anhydrous dimethylsulfoxide (DMSO, 5 mL) in a round bottom flask. The mixture was stirred at room temperature for a few minutes, then DIPEA (0.52 g, 4 mmol) was added. After stirring at 120° C. for 7 h and standing at room temperature for 1 h, the mixture was diluted with water (15 mL) and stirred overnight. The resulting precipitate was collected by suction filtration. Yield 0.25 g (63%). The purity, structure and composition of the product were confirmed by HPLC, NMR and LCMS. MS (DUIS): MW calculated 396.05. Found m / z: (+) 397 (M+1) + ;(-)395(M-1) - .
[0139] [Example 2: Compound I-2: 7-(3-carboxyazetidin-1-yl)-3-(benzoxazol-2-yl)coumarin] [ka] 3-(Benzoxazol-2-yl)-7-fluoro-coumarin (0.56 g, 2 mmol) and 3-carboxyazetidine (0.3 g, 3 mmol) are added to anhydrous dimethylsulfoxide (DMSO, 5 mL) in a round-bottom flask. The mixture is stirred at room temperature for a few minutes, then DIPEA (0.52 g, 4 mmol) is added. After stirring at 125° C. for 9 hours and standing at room temperature for 1 hour, the reaction mixture is diluted with water (10 mL) and stirred overnight. The resulting precipitate is collected by suction filtration. Yield 0.41 g (56%). The purity, structure and composition of the product were confirmed by HPLC, NMR and LCMS. MS (DUIS): MW calculated 362.09. Found m / z: (+) 363 (M+1) + .
[0140] [Example 3. Compound I-3: 7-(3-carboxyazetidin-1-yl)-3-(benzimidazol-2-yl)coumarin] [ka]
[0141] 3-(benzimidazol-2-yl)-7-fluoro-coumarin (FC-2, 0.56 g, 2 mmol, 1 eq.) and 3-carboxyazetidine (AC-C4, 0.3 g, 3 mmol, 1.5 eq.) were added to anhydrous dimethylsulfoxide (DMSO, 5 mL) in a round-bottom flask. The mixture was stirred at room temperature for a few minutes, then DIPEA (0.52 g, 4 mmol) was added. The mixture was stirred at 120° C. for 9 h. An additional portion of 3-carboxyazetidine (0.3 g, 3 mmol) and DIPEA (0.26 g, 2 mmol) was added. After stirring at 120° C. for another 3 h and standing at room temperature for 1 h, the reaction mixture was diluted with water (10 mL) and stirred overnight. The resulting precipitate was collected by suction filtration. Yield 0.26 g (36%). The purity, structure and composition of the product were confirmed by HPLC, NMR and LCMS. MS (DUIS): MW calculated 361.11. Found m / z: (+) 362 (M+1) + ;(-)360(M-1) - .
[0142] [Example 4. Compound I-4: 7-(3-carboxyazetidin-1-yl)-3-(benzothiazol-2-yl)coumarin] [ka] 3-(Benzothiazol-2-yl)-7-fluoro-coumarin (0.30 g, 1 mmol) and 3-carboxyazetidine (0.2 g, 2 mmol) were added to anhydrous dimethylsulfoxide (DMSO, 5 mL) in a round-bottom flask. The mixture was stirred at room temperature for a few minutes, then DIPEA (0.52 g, 4 mmol) was added. After stirring at 120° C. for 8 hours and standing at room temperature for 1 hour, the reaction mixture was diluted with water (10 mL) and stirred overnight. The resulting precipitate was collected by suction filtration. Yield 0.28 g (75%). The purity, structure and composition of the product were confirmed by HPLC, NMR and LCMS. MS (DUIS): MW calculated 378.07. Found m / z: (+) 379 (M+1)+ ;(-)377(M-1) - .
[0143] [Example 5. Compound I-5: 7-(3-carboxypyrrolidinyl-1)-3-(benzothiazol-2-yl)coumarin] [ka] 3-(Benzothiazol-2-yl)-7-fluoro-coumarin (0.30 g, 1 mmol) and 3-carboxypyrrolidine (0.23 g, 2 mmol) were added to anhydrous dimethylsulfoxide (DMSO, 5 mL) in a round-bottom flask. The mixture was stirred at room temperature for a few minutes, then DIPEA (0.52 g, 4 mmol) was added. After stirring at 120° C. for 6 h and standing at room temperature for 1 h, the reaction mixture was diluted with water (20 mL) and stirred overnight. The resulting precipitate was collected by suction filtration. Yield 0.31 g (80%). The purity, structure and composition of the product were confirmed by HPLC, NMR and LCMS. MS (DUIS): MW calculated 392.08. Found m / z: (+) 393 (M+1) + ;(-)391(M-1) - .
[0144] [Example 6. Compound I-6: 7-(4-carboxypiperidin-1-yl)-3-(benzothiazol-2-yl)coumarin] [ka] 3-(Benzothiazol-2-yl)-7-fluoro-coumarin (0.30 g, 1 mmol) and isonipecotic acid (0.26 g, 2 mmol) were added to anhydrous dimethylsulfoxide (DMSO, 5 mL) in a round-bottom flask. The mixture was stirred at room temperature for a few minutes, then DIPEA (0.52 g, 4 mmol) was added. After stirring at 120° C. for 6 h and standing at room temperature for 1 h, the reaction mixture was diluted with water (20 mL) and stirred overnight. The resulting precipitate was collected by suction filtration. Yield 0.34 g (83%). The purity, structure and composition of the product were confirmed by HPLC, NMR and LCMS. MS (DUIS): MW calculated 406.10 Found m / z: (+) 407 (M+1) + ;(-)405(M-1) - .
[0145] [Example 7. Compound I-7: 7-(3-carboxyazetidin-1-yl)-3-(6-sulfo-benzothiazol-2-yl)coumarin] [ka] 7-(3-Carboxyazetidin-1-yl)-3-(benzothiazol-2-yl)coumarin (0.38 g, 1 mmol) was added to 20% oleum (0.5 mL) at about -5°C. The mixture was stirred with cooling for several hours and then at room temperature for 3 hours. After stirring at 80°C for 1 hour and standing at room temperature for 1 hour, the reaction mixture was diluted with anhydrous diethyl ether (10 mL) and stirred overnight. The resulting precipitate was collected by suction filtration. The product was purified by HPLC. Yield 0.1 g (22%). The purity, structure and composition of the product were confirmed by HPLC, NMR and LCMS. MS (DUIS): MW calculated 458.02. Found m / z: (+) 459 (M+1) + .
[0146] [Example 8. Compound I-8: 7-(3-carboxyazetidin-1-yl)-3-(6-sulfamido-benzoxazol-2-yl)coumarin] [ka] 3-(6-Sulfamido-benzoxazol-2-yl)-7-fluoro-coumarin (0.36 g, 1 mmol) and 3-carboxyazetidine (0.3 g, 3 mmol) are added to anhydrous dimethylsulfoxide (DMSO, 5 mL) in a round-bottom flask. The mixture is stirred at room temperature for a few minutes, then DIPEA (0.52 g, 4 mmol) is added. After stirring at 125° C. for 9 hours and standing at room temperature for 1 hour, the reaction mixture is diluted with water (10 mL) and stirred overnight. The resulting precipitate is collected by suction filtration. Yield 0.26 g (60%). The purity, structure and composition of the product were confirmed by HPLC, NMR and LCMS. MS (DUIS): MW calculated 441.06. Found m / z: (+) 442 (M+1) + .
[0147] [Example 9. Comparison of fluorescence intensity] The fluorescence intensity (at maximum excitation wavelength of 450 nm) of the exemplary dye solutions was compared to standard dyes in the same spectral region. The results are shown in Table 1 and demonstrate the significant advantages of the exemplary dyes for fluorescence-based analytical applications. [Table 1]
[0148] Example 10. General procedure for the synthesis of fully functional nucleotide conjugates. The coumarin fluorescent dyes disclosed herein were coupled to the appropriate amino-substituted adenine (A) and cytosine (C) nucleotide derivatives A-LN3-NH2 or C-LN3-NH2: [ka]
[0149] After activating the carboxyl group of the dye with a suitable reagent, according to the following adenine exemplary scheme: [ka]
[0150] Common products for adenine coupling are shown below: [ka] ffA-LN3-Dye refers to a fully functionalized A nucleotide with an LN3 linker and labeled with a coumarin dye as disclosed herein. The R group in each structure refers to the coumarin dye moiety after conjugation.
[0151] The dye (10 μmol) is dried in a 5 mL round-bottom flask and dissolved in anhydrous dimethylformamide (DMF, 1 mL) and the solvent is distilled off in vacuo. This procedure is repeated twice. The dried dye is dissolved in anhydrous N,N-dimethylacetamide (DMA, 0.2 mL) at room temperature. N,N,N',N'-tetramethyl-O-(N-succinimidyl)uronium tetrafluoroborate (TSTU, 1.5 eq., 15 μmol, 4.5 mg) is added to the dye solution, and then DIPEA (3 eq., 30 μmol, 3.8 mg, 5.2 μL) is added to this solution via a micropipette. The reaction flask is sealed under nitrogen gas. The progress of the reaction is monitored by TLC (eluent acetonitrile-water 1:9) and HPLC. Meanwhile, a solution of the appropriate amino-substituted nucleotide derivative (A-LN3-NH2, 20 mM, 1.5 eq, 15 μmol, 0.75 mL) is concentrated in vacuo and redissolved in water (20 μL). The solution of the activated dye in DMA is transferred to the flask containing the solution of N-LN3-NH2. More DIPEA (3 eq, 30 μmol, 3.8 mg, 5.2 μL) is added together with triethylamine (1 μL). The progress of the coupling is monitored every hour by TLC, HPLC, LCMS. Once the reaction is complete, triethylamine bicarbonate buffer (TEAB, 0.05 M ~ 3 mL) is added to the reaction mixture via pipette. An initial purification of the fully functionalized nucleotide is performed by passing the quenched reaction mixture through a DEAE-Sephadex® column to remove most of the remaining unreacted dye. For example, the Sephadex is poured into an empty 25 g Biotage cartridge, solvent system TEAB / MeCN. The solution from the Sephadex column is concentrated in vacuo. The remaining material is redissolved in a minimum amount of water and acetonitrile before filtering through a 20 μm nylon filter. The filtered solution is purified by preparative HPLC. The composition of the prepared compound is confirmed by LCMS.
[0152] A typical product of cytosine coupling is shown below, following a similar procedure as above. [ka] ffC-LN3-dyes refer to fully functionalized C nucleotides bearing an LN3 linker and labeled with the coumarin dyes disclosed herein. The R group in each structure refers to the coumarin dye moiety after conjugation.
[0153] Example 11. Preparation of amide derivatives of compounds of formula (I) Some additional embodiments described herein relate to amide derivatives of compounds of formula (I) and methods for preparing same, the methods comprising converting a compound of formula (Ia) to a compound of formula (Ia') via carboxylic acid activation: [ka] and reacting a compound of formula (Ia') with a primary or secondary amine of formula (Am) to arrive at an amide derivative of formula (Ib): [ka] where the variables X, R, R 1 , R 2 , R 3 , R 4 and n are defined herein; R' is the remaining portion of a carboxyl activator (such as N-hydroxysuccinimide, nitrophenol, pentafluorophenol, HOBt, BOP, PyBOP, DCC, etc.); R A and R B each independently represents hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Carbocyclyl, C 6-10 It is aryl, 5-10 membered heteroaryl, 3-10 membered heterocyclyl, aralkyl, heteroaralkyl, or (heterocyclyl)alkyl.
[0154] General Procedure for the Preparation of Compounds of Formula (Ib) The appropriate dye of formula (Ia) (0.001 mole) is dissolved in an appropriate anhydrous organic solvent (DMF, 1.5 mL). To this solution is added a carboxyl activating reagent such as TSTU, BOP, PyBOP, etc. The reaction mixture is stirred at room temperature for about 20 minutes, and then the appropriate amine derivative is added. The reaction mixture is stirred overnight, filtered, and the excess activating reagent is quenched with a 0.1 M solution of TEAB in water. The solvent is evaporated in vacuum, and the residue is redissolved in TEAB solution and purified by HPLC.
[0155] [Example 12.2 Channel Sequence Use] The efficiency of the novel dye-labeled A nucleotides described herein in sequencing applications has been demonstrated in a two-channel detection method.For the two-channel method described herein, nucleic acids can be sequenced using the method and system described in US Patent Application No. 2013 / 0079232, the disclosure of which is incorporated herein by reference in its entirety.
[0156] In two-channel detection, a nucleic acid can be sequenced by providing a first nucleotide type that is detected in a first channel, a second nucleotide type that is detected in a second channel, a third nucleotide type that is detected in both the first and second channels, and an unlabeled fourth nucleotide type that is not or only minimally detected in either channel. Scatter plots were generated by RTA2.0.93 analysis of the experiment. The scatter plots shown in Figures 1-3 were at cycle 5 of each of the 26 cycle runs.
[0157] Figure 1 shows a scatter plot of fully functionalized nucleotide (ffN) mixtures containing the following: AI-4 (0.5 μM), A-NR550S0 (1.5 μM), C-NR440 (2 μM), DarkG (2 μM), and T-AF550POPOS0 (2 μM) in uptake buffer with Pol812 (blue exposure (channel 1) 500 ms, green exposure (channel 2) 1000 ms; scanned in Scanning mix).
[0158] Figure 2 shows a scatter plot of a fully functionalized nucleotide (ffN) mixture containing the following: AI-5 (1 μM), A-NR550S0 (1 μM), C-NR440 (2 μM), DarkG (2 μM) and T-AF550POPOS0 (2 μM) in uptake buffer with Pol812; blue exposure (channel 1) 500 ms, green exposure (channel 2) 1000 ms; scanned in the Scanning mix.
[0159] Figure 3 shows a scatter plot of a fully functionalized nucleotide (ffN) mixture containing the following: AI-6 (1 μM), A-NR550S0 (1 μM), C-NR440 (2 μM), DarkG (2 μM) and T-AF550POPOS0 (2 μM) in uptake buffer with Pol812; blue exposure (channel 1) 500 ms, green exposure (channel 2) 1000 ms; scanned in the Scanning mix.
[0160] In each of Figures 1-3, the "G" nucleotide is unlabeled and is shown as the bottom left cloud ("dark G"). The signal from a mixture of "A" nucleotides labeled with the novel dyes described herein and a green dye (NR550S0) is shown as the top right cloud in Figures 1-3, respectively. The signal from a "T" nucleotide labeled with the dye AF550POPOS0 is shown as the top left cloud, and the signal from a "C" nucleotide labeled with the dye NR440 is shown as the bottom right cloud. The X-axis indicates the signal intensity of one (blue) channel, and the Y-axis indicates the signal intensity of the other (green) channel. The chemical structures of NR440, AF550POPOS0, and NR550S0 are disclosed in PCT Publication Nos. WO 2018060482A1, WO 2017051201A1, and WO 2014135221A1, respectively, all of which are incorporated by reference.
[0161] Figures 1-3 each show that fully functional A-nucleotide conjugates labeled with the novel dyes described herein provide sufficient signal intensity and excellent cloud separation.
Claims
1. A compound of formula (I), a salt or mesomeric form thereof: 【Chemistry 1】 During the ceremony: X is O, S, Se, or NR n Wherein R n is H, C 1-6 Alkyl, or C 6-10 is aryl; Ring A is a 3- to 10-membered heterocyclyl; R, R 1 , R 2 , and R 4 are each independently H, halo, -CN, -CO 2 H, amino, -OH, C-amide, N-amide, NO 2 , -SO 3 H, -SO 2 N.R. a R b , optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aminoalkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; Each R 3 are independently -CO 2 H or -(CH 2 ) p -CO 2 R c and p is 1, 2, 3, or 4; Each R 5 are independently halo, -CN, -CO 2 R f , amino, -OH, C-amide, N-amide, -NO 2 , -SO 3 H, -SO 2 N.R. a R b , optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aminoalkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; Each R a and R b are independently H or optionally substituted C 1-6 is alkyl; Each Rc and R f are independently H, an optionally substituted C 1-6 alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; m is 0, 1, 2, 3, or 4; and n is 1.
2. 2. The compound of claim 1, wherein X is O or S.
3. X is NR n 2. The compound of claim 1 ,
4. R is H, halo, -CO 2 H, amino, -OH, C-amide, N-amide, -NO 2 , -SO 3 H, -SO 2 N.H. 2 4. The compound of claim 1, wherein R is an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted alkoxy, an optionally substituted aminoalkyl, an optionally substituted carbocyclyl, an optionally substituted heterocyclyl, an optionally substituted aryl, or an optionally substituted heteroaryl.
5. R is H, halo, or C 1-6 The compound of claim 4, which is alkyl.
6. 6. The compound of claim 5, wherein R is H.
7. R 1 is H, halo, or C 1-6 The compound according to any one of claims 1 to 6, which is alkyl.
8. R 1 The compound of claim 7, wherein is H.
9. R 2 But, H, SO 3 H, optionally substituted alkyl, or optionally -CO 2 H or -SO 3 C substituted with H 1-4 The compound according to any one of claims 1 to 8, which is alkyl.
10. R 2 is H or -SO 3 10. The compound of claim 9, wherein:
11. R 4 H, -SO 3 H, optionally substituted alkyl, or optionally -CO 2 H or -SO 3 C substituted with H 1-4 The compound according to any one of claims 1 to 10, which is alkyl.
12. R 4 is H or -SO 3 12. The compound of claim 11 , wherein R is H.
13. The compound according to any one of claims 1 to 12, wherein ring A is a 3- to 7-membered monoheterocyclic ring containing one nitrogen atom.
14. Ring A is 【Chemistry 2】 The compound according to any one of claims 1 to 13,
15. Each R 5 Halo, -CN, -CO 2 H, -SO 3 H, -SO 2 N.R. a R b or optionally substituted C 1-6 The compound according to any one of claims 1 to 14, which is alkyl.
16. R 5 But -CO 2 H, -SO 3 H, -SO 2 N.H. 2 or -CO 2 H, -SO 3 H, or -SO 2 N.H. 2 C substituted with 1-6 The compound of claim 15 which is alkyl.
17. X is O, S, or NH; each R, R 1 , R 2 , and R 4 is H; Ring A is 【Chemistry 3】 m is 0 or 1; and R 5 But halo, -CO 2 H, -SO 3 H, -SO 2 N.H. 2 , or -SO 3 H or -SO 2 N.H. 2 C substituted with 1-6 The compound of claim 1 , wherein the aryl group is an alkyl group.
18. the below described: 【Chemistry 4】 2. The compound of claim 1, selected from the group consisting of: and salts and mesomeric forms thereof.
19. The compound according to any one of claims 1 to 18, wherein the compound is linked to a nucleotide or an oligonucleotide.
20. A nucleotide or oligonucleotide labelled with a compound according to any one of claims 1 to 18.
21. The compound is represented by formula (I) 3 The labeled nucleotide or oligonucleotide of claim 20, wherein the nucleotide or oligonucleotide is linked to the nucleotide or oligonucleotide via
22. R in formula (I) 3 But -CO 2 H or -(CH 2 ) p -CO 2 H and the bond is -CO 2 22. The labeled nucleotide or oligonucleotide of claim 21, wherein the H group is used to form an amide.
23. The compound is represented by formula (I) 5 The labeled nucleotide or oligonucleotide of claim 20, wherein the nucleotide or oligonucleotide is linked to the nucleotide or oligonucleotide via
24. R in formula (I) 5 But -CO 2 H and the bond is -CO 2 24. The labeled nucleotide or oligonucleotide of claim 23, wherein the H group is used to form an amide.
25. 25. The labeled nucleotide or oligonucleotide of any one of claims 20 to 24, wherein the compound is attached via a linker moiety to the C5 position of a pyrimidine base or the C7 position of a 7-deazapurine base.
26. 26. The labeled nucleotide or oligonucleotide of any one of claims 20 to 25, further comprising a 3'OH blocking group covalently attached to the ribose or deoxyribose sugar of the nucleotide.
27. A kit comprising a first labeled nucleotide and a second labeled nucleotide according to any one of claims 20 to 26.
28. 28. The kit of claim 27, wherein the second labeled nucleotide is labeled with a different compound than the first labeled nucleotide.
29. 30. The kit of claim 28, wherein the first and second labeled nucleotides are excitable using a single laser wavelength.
30. 30. The kit of claim 28 or 29, further comprising a third nucleotide and a fourth nucleotide, wherein each of the second, third, and fourth nucleotides is labeled with a different compound, and each label has a different absorption maximum distinguishable from the other labels.
31. 28. The kit of claim 27, wherein the kit comprises four nucleotides, a first of the four nucleotides being a labeled nucleotide according to any one of claims 20 to 26, a second of the four nucleotides carrying a second label, a third nucleotide carrying a third label, and a fourth nucleotide being unlabeled.
32. 28. The kit of claim 27, wherein the kit comprises four nucleotides, a first of the four nucleotides being a labeled nucleotide according to any one of claims 20 to 26, a second of the four nucleotides carrying a second label, a third nucleotide carrying a mixture of two labels, and a fourth nucleotide being unlabeled.
33. Use of a compound according to any one of claims 1 to 18, a labelled nucleotide or oligonucleotide according to claims 20 to 26, or a kit according to any one of claims 27 to 32 in sequencing, expression analysis, hybridisation analysis, genetic analysis, RNA analysis or protein binding assays.
34. 34. The use of claim 33 on an automated sequencing device, said automated sequencing device comprising two lasers operating at different wavelengths.
35. A method of sequencing comprising incorporating a labeled nucleotide according to any one of claims 20 to 26 in a sequencing assay.
36. 36. The method of claim 35, further comprising detecting the labeled nucleotide.
37. 37. The method of claim 35 or 36, wherein the sequencing assay is performed on an automated sequencing device, the automated sequencing device comprising two light sources operating at different wavelengths.
38. Formula (I): 【Chemistry 5】 A method for the synthesis of a compound of formula (II) comprising reacting a compound of formula (II) with an optionally substituted cyclic amine of formula (III): 【Chemistry 6】 [In the formulas (I), (II), and (III): X is O, S, Se, or NR n Wherein R n is H, C 1-6 Alkyl, or C 6-10 is aryl; Ring A is a 3- to 10-membered heterocyclyl; R, R 1 , R 2 , and R 4 are each independently H, halo, -CN, -CO 2 H, amino, -OH, C-amide, N-amide, NO 2 , -SO 3 H, -SO 2 N.R. a R b , optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aminoalkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; Each R 3 are independently -CO 2 H or -(CH 2 ) p -CO 2 R c and p is 1, 2, 3, or 4; Each R 5 are independently halo, -CN, -CO 2 R f , amino, -OH, C-amide, N-amide, -NO 2 , -SO 3 H, -SO 2 N.R. a R b , optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aminoalkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; Each R a and R b are independently H or optionally substituted C 1-6 is alkyl; Each Rc and R f are independently H, an optionally substituted C 1-6 alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; m is 0, 1, 2, 3, or 4; and n is 1. A method comprising:
Citation Information
Patent Citations
Sulfocoumarin-containing nucleotides and their use in detection of nucleic acid
JP1994271599A
Colored curable resin composition
JP2013231165A
Compounds for treating spinal muscular atrophy
WO2013101974A1
Methods for modulating the amount RNA transcripts
WO2015095449A1
New fluorescent DYES and their uses as biomarkers
WO2018060482A1
